08:39 , Apr 3, 2019 |  BC Extra  |  Financial News

AgomAb emerges from stealth with €21M series A

Agonist antibody company AgomAb emerged from stealth with a €21 million ($24 million) series A round led by V-Bio Ventures and Advent France Biotechnology to develop antibodies mimicking growth factors for tissue regeneration. AgomAb Therapeutics...